

SoonerCare





Adstiladrin® (Nadofaragene Firadenovec-vngc) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
☐ <i>Physician billing</i> (HCPCS	de:)	
Dose:Regin	nen: Start Da	ate (or date of next dose):
Billing Provider Information		
Provider NPI:	Provider Name:	
	Provider Fax:	
Name of outpatient health of	are facility where Adstiladrin [®] will be	delivered to and administered at:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Control Contr		
*For Initial Authorization:		
A. Does member tumors? Yes B. Does member (BCG) therap	sive Bladder Cancer (NMIBC) or have a diagnosis of NMIBC with carci	-
Yes No No	evidence of progressive disease whed adverse drug reactions related to	nile on nadofaragene firadenovec-vngc? nadofaragene firadenovec-vngc
rescriber Signature: Date: Date: Date:		
knowledge. Please do not send	in chart notes. Specific information will be re	equested if necessary. Failure to

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

complete this form in full and attach requested clinical notes will result in processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 242 7/20/2023